Tianjin Zhongxin Pharmaceutical Group Corp Ltd (SHG:600329) — Market Cap & Net Worth
Market Cap & Net Worth: Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)
Tianjin Zhongxin Pharmaceutical Group Corp Ltd (SHG:600329) has a market capitalization of $2.93 Billion (CN¥20.01 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #5041 globally and #877 in its home market, demonstrating a 1.36% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tianjin Zhongxin Pharmaceutical Group Corp Ltd's stock price CN¥35.10 by its total outstanding shares 570094356 (570.09 Million). Also see Tianjin Zhongxin Pharmaceutical Group Co (600329) total assets for a full breakdown of the balance sheet.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Market Cap History: 2015 to 2026
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.56 Billion to $2.93 Billion (6.97% CAGR). Also see Tianjin Zhongxin Pharmaceutical Group Co operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 600329 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.35x
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap is 0.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.15x
Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap is 1.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.56 Billion | $7.08 Billion | $451.44 Million | 0.22x | 3.47x |
| 2016 | $1.31 Billion | $6.24 Billion | $423.60 Million | 0.21x | 3.08x |
| 2017 | $1.12 Billion | $5.69 Billion | $476.08 Million | 0.20x | 2.36x |
| 2018 | $948.43 Million | $6.36 Billion | $561.68 Million | 0.15x | 1.69x |
| 2019 | $1.07 Billion | $6.99 Billion | $625.57 Million | 0.15x | 1.72x |
| 2020 | $1.38 Billion | $6.60 Billion | $661.70 Million | 0.21x | 2.09x |
| 2021 | $2.51 Billion | $6.91 Billion | $769.14 Million | 0.36x | 3.26x |
| 2022 | $2.38 Billion | $8.25 Billion | $861.79 Million | 0.29x | 2.76x |
| 2023 | $2.81 Billion | $8.22 Billion | $986.71 Million | 0.34x | 2.84x |
| 2024 | $2.57 Billion | $7.31 Billion | $2.23 Billion | 0.35x | 1.15x |
Competitor Companies of 600329 by Market Capitalization
Companies near Tianjin Zhongxin Pharmaceutical Group Corp Ltd in the global market cap rankings as of September 24, 2026. Review tangible equity quality of Tianjin Zhongxin Pharmaceutical Group Co to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tianjin Zhongxin Pharmaceutical Group Corp Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Tianjin Zhongxin Pharmaceutical Group Corp Ltd's market cap moved from $1.56 Billion to $ 2.93 Billion, with a yearly change of 6.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.93 Billion | -23.06% |
| 2025 | CN¥3.81 Billion | +48.12% |
| 2024 | CN¥2.57 Billion | -8.47% |
| 2023 | CN¥2.81 Billion | +18.15% |
| 2022 | CN¥2.38 Billion | -5.20% |
| 2021 | CN¥2.51 Billion | +81.66% |
| 2020 | CN¥1.38 Billion | +28.59% |
| 2019 | CN¥1.07 Billion | +13.13% |
| 2018 | CN¥948.43 Million | -15.56% |
| 2017 | CN¥1.12 Billion | -14.02% |
| 2016 | CN¥1.31 Billion | -16.52% |
| 2015 | CN¥1.56 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Tianjin Zhongxin Pharmaceutical Group Corp Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.93 Billion USD |
| MoneyControl | $2.93 Billion USD |
| MarketWatch | $2.93 Billion USD |
| marketcap.company | $2.93 Billion USD |
| Reuters | $2.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more